PMV Pharmaceuticals Inc., a Cranbury-based oncology therapy company, raised about $211.8 million through its initial public offering, it announced last week.
The company, which is pioneering the discovery and development of small-molecule therapies targeting certain mutations, sold 11.765 million shares of common stock at $18 per share on the Nasdaq Global Select Market last Thursday. The stock closed at $37.51 Friday, up 108.4%.
The stock trades under the symbol PVMP.
Goldman Sachs & Co. LLC, BofA Securities, Cowen and Evercore ISI are the joint book-running managers for the offering.